Brinda Balakrishnan/LinkedIn
Dec 22, 2025, 12:39
Shining a Light on von Willebrand Disease: An Often Overlooked Bleeding Disorder
Brinda Balakrishnan, Board Member of Aurinia Pharmaceuticals Inc., shared a post by Star Therapeutics on LinkedIn:
“There continue to be many sizable, rare disorders with few to no therapeutic options. Glad that Star is shining a light on VWD and developing novel medicines to address patient needs!”
Quoting Star Therapeutics‘ post:
“von Willebrand Disease is often overlooked compared to other bleeding disorders like hemophilia, leaving many patients without the resources and support they deserve.
Listen as Nick shares his experience growing up with a condition that was frequently misunderstood and the impact that has had on his journey with VWD.”
Find more related posts on Hemostasis Today.
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH
-
Oct 16, 2026, 10:07Habib Bennaceur: Building a Stronger Care Pathway for Sickle Cell Disease in India
-
Oct 16, 2026, 09:59Tareq Abadl: A Simple Guide to Blood Collection Tubes
-
Oct 16, 2026, 09:50Mona Alfaraj: Distinguishing HCL from SMZL in Bone Marrow